MediWound's $12.50 Bought Deal Grows to $17.25M as Wainwright Exercises Full Option
MDWD is trading near its 52-week low of $11.8 (13% above the low).
Summary
MediWound closed the books on its bought deal: 1,380,000 shares at $12.50 for about $17.25 million gross after H.C. Wainwright exercised its full 180,000-share option, equal to roughly 10.6% dilution of the 13,010,217 shares outstanding.
Key Events · Financing and Capital Events · MDWD
-
Bought Deal Upsized to $17.25M
Wainwright exercised in full its 30-day option on November 4, 2026 for 180,000 additional shares, bringing the total to 1,380,000 ordinary shares at $12.50 each and gross proceeds to approximately $17.25 million.
-
Roughly 10.6% Dilution
The 1,380,000 new shares equal about 10.6% of the 13,010,217 shares outstanding before the deal (1,380,000 / 13,010,217); net proceeds fund working capital and general corporate purposes.
-
Priced Below Last Reported Sale
The $12.50 offering price compares with the $13.50 last reported Nasdaq sale price on November 2, 2026, a modest discount to the pre-announcement level.
-
Lock-Ups and Underwriter Fees
The company agreed to a 60-day issuance lock-up and directors and executive officers signed matching lock-ups; Wainwright receives $100,000 in legal fee reimbursement, $25,000 non-accountable expenses, $15,950 clearing costs and a discretionary bonus of up to $500,000.
Analysis · MDWD · Life Sciences
The 6-K formalizes the underwriting agreement behind MediWound's already-announced equity raise and confirms the underwriter took the entire 180,000-share greenshoe, pushing gross proceeds to about $17.25 million from roughly $15 million. For a company that burned about $20 million in the first half of 2026 and reaffirmed full-year revenue guidance of $24-26 million, that extra cash buys runway—but at the cost of roughly 10.6% dilution (1,380,000 new shares against 13,010,217 existing). Pricing at $12.50 was below the $13.50 last reported Nasdaq sale on November 2, 2026, so the deal cleared at a modest discount to the pre-announcement price. Near-term secondary supply is removed by the 60-day company lock-up and matching director/officer lock-ups, and the discretionary bonus of up to $500,000 payable to Wainwright is an unusual cost worth noting.
How filings like this one have moved
In the 30 days to Nov 5, 2026, 33.3% of the 2367 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was +0.01%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MDWD was trading at $13.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $171.6M. The 52-week trading range was $11.80 to $19.70. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.